7
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) human adaptation resulted in distinct lineages with enhanced transmissibility called variants of concern (VOCs). Omicron is the first VOC to evolve distinct globally dominant subvariants. Here we compared their replication in human cell lines and primary airway cultures and measured host responses to infection. We discovered that subvariants BA.4 and BA.5 have improved their suppression of innate immunity when compared with earlier subvariants BA.1 and BA.2. Similarly, more recent subvariants (BA.2.75 and XBB lineages) also triggered reduced innate immune activation. This correlated with increased expression of viral innate antagonists Orf6 and nucleocapsid, reminiscent of VOCs Alpha to Delta. Increased Orf6 levels suppressed host innate responses to infection by decreasing IRF3 and STAT1 signalling measured by transcription factor phosphorylation and nuclear translocation. Our data suggest that convergent evolution of enhanced innate immune antagonist expression is a common pathway of human adaptation and link Omicron subvariant dominance to improved innate immune evasion.

          Abstract

          SARS-CoV-2 adaptation and evolution led to stronger innate immune suppression by increasing expression of Orf6 in Omicron subvariants.

          Related collections

          Most cited references77

          • Record: found
          • Abstract: found
          • Article: not found

          Fiji: an open-source platform for biological-image analysis.

          Fiji is a distribution of the popular open-source software ImageJ focused on biological-image analysis. Fiji uses modern software engineering practices to combine powerful software libraries with a broad range of scripting languages to enable rapid prototyping of image-processing algorithms. Fiji facilitates the transformation of new algorithms into ImageJ plugins that can be shared with end users through an integrated update system. We propose Fiji as a platform for productive collaboration between computer science and biology research communities.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

            Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              U1 snRNP regulates cancer cell migration and invasion in vitro

              Stimulated cells and cancer cells have widespread shortening of mRNA 3’-untranslated regions (3’UTRs) and switches to shorter mRNA isoforms due to usage of more proximal polyadenylation signals (PASs) in introns and last exons. U1 snRNP (U1), vertebrates’ most abundant non-coding (spliceosomal) small nuclear RNA, silences proximal PASs and its inhibition with antisense morpholino oligonucleotides (U1 AMO) triggers widespread premature transcription termination and mRNA shortening. Here we show that low U1 AMO doses increase cancer cells’ migration and invasion in vitro by up to 500%, whereas U1 over-expression has the opposite effect. In addition to 3’UTR length, numerous transcriptome changes that could contribute to this phenotype are observed, including alternative splicing, and mRNA expression levels of proto-oncogenes and tumor suppressors. These findings reveal an unexpected role for U1 homeostasis (available U1 relative to transcription) in oncogenic and activated cell states, and suggest U1 as a potential target for their modulation.
                Bookmark

                Author and article information

                Contributors
                a.reuschl@ucl.ac.uk
                c.jolly@ucl.ac.uk
                g.towers@ucl.ac.uk
                Journal
                Nat Microbiol
                Nat Microbiol
                Nature Microbiology
                Nature Publishing Group UK (London )
                2058-5276
                16 January 2024
                16 January 2024
                2024
                : 9
                : 2
                : 451-463
                Affiliations
                [1 ]Division of Infection and Immunity, University College London, ( https://ror.org/02jx3x895) London, UK
                [2 ]Department of Infectious Diseases, St Mary’s Medical School, Imperial College London, ( https://ror.org/041kmwe10) London, UK
                [3 ]Epithelial Stem Cell Biology and Regenerative Medicine Laboratory, The Francis Crick Institute, ( https://ror.org/04tnbqb63) London, UK
                [4 ]MRC-University of Glasgow Centre for Virus Research, ( https://ror.org/03vaer060) Glasgow, UK
                [5 ]COVID Surveillance Unit, The Francis Crick Institute, ( https://ror.org/04tnbqb63) London, UK
                Author information
                http://orcid.org/0000-0002-1459-3519
                http://orcid.org/0000-0001-7358-6047
                http://orcid.org/0000-0003-0441-3358
                http://orcid.org/0000-0003-2186-293X
                http://orcid.org/0000-0002-5588-4232
                http://orcid.org/0000-0003-1813-7825
                http://orcid.org/0000-0002-2736-8740
                http://orcid.org/0000-0002-7109-4011
                http://orcid.org/0000-0001-9655-3766
                http://orcid.org/0000-0001-7007-4070
                http://orcid.org/0000-0003-4600-2047
                http://orcid.org/0000-0002-4603-2281
                http://orcid.org/0000-0002-7707-0264
                Article
                1588
                10.1038/s41564-023-01588-4
                10847042
                38228858
                a82f970b-3a88-4683-8dad-9878c1342889
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 22 July 2022
                : 13 December 2023
                Funding
                Funded by: FundRef https://doi.org/10.13039/100004440, Wellcome Trust (Wellcome);
                Award ID: 223065
                Award ID: 227004/Z/23/Z
                Award ID: 206369/Z/17/Z
                Award ID: 220863
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100009187, RCUK | MRC | Medical Research Foundation;
                Award ID: MR/Y004205/1
                Award ID: MR/Y004205/1
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100000265, RCUK | Medical Research Council (MRC);
                Award ID: MR/Y004205/1
                Award ID: MR/W005611/1
                Award ID: MC_UU12014/2
                Award ID: MC_UU_00034/9
                Award ID: MR/W005611/1
                Award ID: MR/W005611/1
                Award Recipient :
                Funded by: NIHR Biomedical Research Centre at UCLH
                Funded by: Marie Skłodowska-Curie Individual Fellowships no. 896014
                Funded by: FundRef https://doi.org/10.13039/501100000833, Rosetrees Trust;
                Award ID: M362-F1; M553
                Award Recipient :
                Funded by: European Research Council ERC-Stg no. 639429 NIHR GOSH BRC and the CF Trust (SRC006; SRC020)
                Categories
                Article
                Custom metadata
                © Springer Nature Limited 2024

                sars-cov-2,virus-host interactions,innate immunity
                sars-cov-2, virus-host interactions, innate immunity

                Comments

                Comment on this article